Eric Small, MD
Enriched profileProfessor of Medicine and Urology (UCSF Urology lists as "Professor of Medicine, Hematology Oncology and Urology"; UCSF Cancer Center lists as "Professor In Residence of Medicine and Urology", minor wording variants across UCSF's own pages, not a conflict); Co-Leader, UCSF Prostate Cancer Program; Deputy Director and Chief Scientific Officer, UCSF Helen Diller Family Comprehensive Cancer Center; President, American Society of Clinical Oncology (2025-2026) · University of California, San Francisco (UCSF)
Eric Small is Professor of Medicine and Urology (UCSF Urology lists as "Professor of Medicine, Hematology Oncology and Urology"; UCSF Cancer Center lists as "Professor In Residence of Medicine and Urology", minor wording variants across UCSF's own pages, not a conflict); Co-Leader, UCSF Prostate Cancer Program; Deputy Director and Chief Scientific Officer, UCSF Helen Diller Family Comprehensive Cancer Center; President, American Society of Clinical Oncology (2025-2026) at University of California, San Francisco (UCSF). OpenAlex indexes 1,319 publications with 69,136 citations (h-index 119); ClinicalTrials.gov lists 13 registered studies with this person as an investigator. Clarivate lists Eric Small as a Highly Cited Researcher (Clinical Medicine, 2018-2021).
Data verified 24 Aug 2026
Overview
Updated 13 Oct 2026
Eric J. Small, MD, is Professor of Medicine and Urology (UCSF Urology lists as "Professor of Medicine, Hematology Oncology and Urology" at University of California, San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center / Department of Medicine, Division of Hematology-Oncology. The public record shows 1,319 publications with 69,136 citations (h-index 119), centered on Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Radiopharmaceutical Chemistry and Applications. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 3 companies, 4 NIH-funded awards (1995–2026).
- Most recent indexed publication: 2025 · Nature communications
- Top research focus: Prostate Cancer Treatment and Research
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 3 companies
Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 28 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 447.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- As ASCO President
advocated for reform of the 340B Drug Pricing Program (eligibility, transparency, and accountability updates) to reflect modern oncology care delivery
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asco.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →globalhealthsciences.ucsf.edu ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Oct 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- Radiologically Guided Biopsies of mCRPC
Sponsor: University of California, San Francisco
- Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)
Sponsor: University of California, San Francisco
Industry payments
Updated 13 Oct 2026
3 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- Janssen Research & Development, LLCProgram year20241 payment
- Janssen Research & Development, LLCProgram year20232 payments
- Deciphera Pharmaceuticals Inc.Program year20231 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
78.1%Gonadotropin Releasing Hormone Receptor Agonist38.4%Leuprolide acetate100%Part B, office-administered≥14 patientsAnti-androgens21.1%Erleada54%Nubeqa46%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
21.9%Corticosteroid21.9%Prednisone100%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 13 Oct 2026
4 NIH research awards on record, funded 1995–2026 per NIH RePORTER. The latest:
- UCSF Specialized Programs of Research Excellence (SPOREs) in Prostate Cancer
University of California, San Francisco
FY2026$2,178,091P50CA275741 - Establishing the role of exercise in the maintenance of a cardioprotective stress response
University of Rochester
FY2026$665,724R01HL178616 - Intercalated disc-nuclear lamina coupling as a molecular substrate for arrhythmogenic cardiomyopathy
University of Rochester
FY2026$658,771R01HL169961
Publications
Updated 13 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer.
Nature communications
Clinical Trial2025 - Racial variation in the advanced prostate cancer genome.
Prostate cancer and prostatic diseases
Article2025 - Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer.
Journal of clinical oncology
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)Network
Updated 13 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 13 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/eric-small-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
connection.asco.org/do/dr-eric-j-small-elected-asco-president-2025-2026-term
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →connection.asco.org ↗ - Other
en.wikipedia.org/wiki/Eric._J._Small
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗ - Other
grandroundsinurology.com/author/esmall
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →grandroundsinurology.com ↗ - Other
profiles.ucsf.edu/eric.small
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗ - LinkedIn
LinkedIn profile listing him as 'ASCO President, 2025-2026.
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Doximity
Doximity professional profile, Oncology, San Francisco, CA (direct fetch succeeded; confirmed name/credential/UCSF institution match …
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →society.asco.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.ucsf.edu ↗
- Internal Medicine Internship/Residency
Beth Israel Hospital (now Beth Israel Deaconess Medical Center), Boston
1988verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.ucsf.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.ucsf.edu ↗
- Board Certified
Internal Medicine, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsf.edu ↗
- Founding Scientific Program Chair
ASCO Genitourinary Cancers Symposium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.ucsf.edu ↗
- Chair
Prostate Cancer Correlative Sciences Working Group, Cancer and Leukemia Group B (CALGB)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urology.ucsf.edu ↗ - Board of Directors
American Prostate Cancer Foundation (CaP CURE Therapy Consortium)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urology.ucsf.edu ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine2018201920202021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealthhemonc.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.ucsf.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.ucsf.edu ↗
- Co-director
UCSF Urologic Cancer Service, Department of Urology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urology.ucsf.edu ↗ - Former Chief
Division of Hematology and Oncology, UCSF Department of Medicine (10-year tenure)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connection.asco.org ↗
- "Multicultural ASCO President-Elect Was Raised in Mexico by Parents Who Instilled a Sense of Duty to Make a Difference"
narrative profile, The ASCO Post
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - "Science Matters" podcast/video series host
discussing translational cancer science as part of ASCO presidential theme
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connection.asco.org ↗ - "In Conversation: UCSF Oncologist and ASCO President Eric Small"
interview feature, UCSF Institute for Global Health Sciences
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →globalhealthsciences.ucsf.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Miller, MD
University of California, San Francisco (UCSF)
Gregory Marcus, MD
University of California, San Francisco (UCSF)
Adam Boxer, MD
University of California, San Francisco (UCSF)
Bruce Cree, MD
University of California, San Francisco (UCSF)
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)